TY - JOUR
T1 - Effect of 20-hydroxyecdysone and its metabolites in the absence or presence of IGF-1 on regulation of skeletal muscle cell growth
AU - Suhatcho, Kanokwan
AU - Yingyongnarongkul, Boon Ek
AU - Kumpun, Saowanee
AU - Srikuea, Ratchakrit
N1 - Publisher Copyright:
© 2023 The authors.
PY - 2023
Y1 - 2023
N2 - Purpose: To investigate the effect of 20-hydroxyecdysone (20E) and its metabolites and their synergistic effect with IGF-1 on regulation of skeletal muscle cell growth. Methods: Mouse skeletal muscle cell line (C2C12) was solely treated with 20E and its metabolites (14-deoxy-20-hydroxyecdysone, poststerone, and 14-deoxypoststerone) at doses of 0.1, 1, and 10 µM or co-treated with IGF-1 (10 ng/ml). Cell viability and proliferative capacity were evaluated using MTT and BrdU incorporation assays, respectively. Myogenic differentiation proteins [embryonic myosin heavy chain (EbMHC) and MHC], androgen receptor (AR), and IGF-1 receptor (IGF-1R) protein expression were investigated using immunocytochemistry. Results: Treatments of 20E and its metabolites had no toxicity on skeletal muscle cells or induced AR/IGF-1R expression. In addition, solely treatment of 20E and its metabolites or co-treatment with IGF-1 had no significant effect on cell proliferation and myogenic differentiation capacity. In contrast, IGF-1 treatment alone significantly increased EbMHC expression (p<0.0001), MHC expression (p<0.05), and myotube number (p<0.05). Conclusion: These results indicate that 20E and its metabolites have no direct or synergistic effect with IGF-1 on skeletal muscle cell growth. Nevertheless, the pharmacological effects of 20E on skeletal muscle mass and strength in vivo that raises its therapeutic potential may associate with its indirect action.
AB - Purpose: To investigate the effect of 20-hydroxyecdysone (20E) and its metabolites and their synergistic effect with IGF-1 on regulation of skeletal muscle cell growth. Methods: Mouse skeletal muscle cell line (C2C12) was solely treated with 20E and its metabolites (14-deoxy-20-hydroxyecdysone, poststerone, and 14-deoxypoststerone) at doses of 0.1, 1, and 10 µM or co-treated with IGF-1 (10 ng/ml). Cell viability and proliferative capacity were evaluated using MTT and BrdU incorporation assays, respectively. Myogenic differentiation proteins [embryonic myosin heavy chain (EbMHC) and MHC], androgen receptor (AR), and IGF-1 receptor (IGF-1R) protein expression were investigated using immunocytochemistry. Results: Treatments of 20E and its metabolites had no toxicity on skeletal muscle cells or induced AR/IGF-1R expression. In addition, solely treatment of 20E and its metabolites or co-treatment with IGF-1 had no significant effect on cell proliferation and myogenic differentiation capacity. In contrast, IGF-1 treatment alone significantly increased EbMHC expression (p<0.0001), MHC expression (p<0.05), and myotube number (p<0.05). Conclusion: These results indicate that 20E and its metabolites have no direct or synergistic effect with IGF-1 on skeletal muscle cell growth. Nevertheless, the pharmacological effects of 20E on skeletal muscle mass and strength in vivo that raises its therapeutic potential may associate with its indirect action.
KW - 20-hydroxyecdysone
KW - C2C12
KW - IGF-1
KW - Vitex glabrata
KW - androgen receptor
KW - metabolite
KW - skeletal muscle
UR - http://www.scopus.com/inward/record.url?scp=85177561429&partnerID=8YFLogxK
U2 - 10.4314/tpr.v22i10.11
DO - 10.4314/tpr.v22i10.11
M3 - Article
AN - SCOPUS:85177561429
SN - 1596-5996
VL - 22
SP - 2099
EP - 2110
JO - Tropical Journal of Pharmaceutical Research
JF - Tropical Journal of Pharmaceutical Research
IS - 10
ER -